LLY

986

-0.26%↓

JNJ

224.47

-0.51%↓

ABBV

204.99

-0.5%↓

UNH

366.96

+0.87%↑

AZN

184.44

+1.73%↑

LLY

986

-0.26%↓

JNJ

224.47

-0.51%↓

ABBV

204.99

-0.5%↓

UNH

366.96

+0.87%↑

AZN

184.44

+1.73%↑

LLY

986

-0.26%↓

JNJ

224.47

-0.51%↓

ABBV

204.99

-0.5%↓

UNH

366.96

+0.87%↑

AZN

184.44

+1.73%↑

LLY

986

-0.26%↓

JNJ

224.47

-0.51%↓

ABBV

204.99

-0.5%↓

UNH

366.96

+0.87%↑

AZN

184.44

+1.73%↑

LLY

986

-0.26%↓

JNJ

224.47

-0.51%↓

ABBV

204.99

-0.5%↓

UNH

366.96

+0.87%↑

AZN

184.44

+1.73%↑

Inicio・Lista de Acciones・Ultragenyx Pharmaceutical Inc

Ultragenyx Pharmaceutical Inc

Cerrado

SectorSanidad

25.93 4.05

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

24.21

Máximo

27.03

Métricas clave
By Trading Economics
Ingresos	51M -129M
Ventas	207M
Margen de beneficios	-62.319
Empleados	1,371
EBITDA	8.8M -105M

Recomendaciones
By TipRanks
Recomendaciones	Compra Fuerte
Estimación a 12 Meses	+111.85% upside

Dividendos
By Dow Jones
Próximas Ganancias	4 ago 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	460M 2.4B
Apertura anterior	21.88
Cierre anterior	25.93

Noticias sobre sentimiento de mercado

By Acuity

40%

60%

154 / 347 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Very Strong Bearish Evidence

32.76 / 39.24 Soporte y Resistencia

Ultragenyx Pharmaceutical Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

6 may 2026, 23:41 UTC

Ganancias

Arm Holdings Lacks Supply to Meet Roaring Demand for New Chips -- Update

6 may 2026, 21:40 UTC

Ganancias

Nutrien Logs Higher Profit, Sales Growth in 1Q

6 may 2026, 23:47 UTC

Charlas de Mercado

Nikkei May Rise on Hopes for U.S.-Iran Peace Talks -- Market Talk

6 may 2026, 23:34 UTC

Charlas de Mercado

Gold Prices Steady, Supported by Lower U.S. Treasury Yields -- Market Talk

6 may 2026, 23:13 UTC

Ganancias

Kakao 1Q Net Profit Beat FactSet-Compiled Consensus

6 may 2026, 23:13 UTC

Ganancias

Kakao 1Q Net KRW226.84B Vs. Net KRW200.33B >035720.SE

6 may 2026, 23:12 UTC

Ganancias

Kakao 1Q Oper Pft KRW211.40B Vs. Pft KRW105.40B >035720.SE

6 may 2026, 23:11 UTC

Ganancias

Kakao 1Q Rev KRW1.942T Vs. KRW1.864T >035720.SE

6 may 2026, 23:11 UTC

Ganancias

United Overseas Bank's CEO: Low Single-Digit Loan Growth Outlook for 2026 >U11.SG

6 may 2026, 23:11 UTC

Ganancias

United Overseas Bank's CEO: 2026 Outlook for Total Credit Costs at 25-30 Basis Points >U11.SG

6 may 2026, 23:11 UTC

Ganancias

United Overseas Bank's CEO: Low Single-Digit Operating Cost Growth Outlook for 2026>U11.SG

6 may 2026, 23:11 UTC

Ganancias

United Overseas Bank's CEO: 2026 Outlook for Full-Year NIM of 1.75%-1.80% >U11.SG

6 may 2026, 23:11 UTC

Ganancias

United Overseas Bank's CEO: High Single-Digit Fee Growth Outlook for 2026 >U11.SG

6 may 2026, 23:07 UTC

Ganancias

United Overseas Bank: 1Q Net Profit Decline Reflects Softer Operating Environment >U11.SG

6 may 2026, 23:06 UTC

Ganancias

United Overseas Bank 1Q Net Fee Income S$637M Vs. S$694M >U11.SG

6 may 2026, 23:06 UTC

Ganancias

United Overseas Bank 1Q Net Interest Income S$2.32B Vs. S$2.41B >U11.SG

6 may 2026, 23:05 UTC

Ganancias

United Overseas Bank 1Q Net S$1.44B Vs. Net S$1.49B >U11.SG

6 may 2026, 23:04 UTC

Ganancias

United Overseas Bank 1Q Total Income S$3.42B Vs. S$3.66B >U11.SG

6 may 2026, 22:50 UTC

Ganancias

Sarepta Stock Sinks on Earnings Beat. Elevidys Demand Faces a Reality Check. -- Barrons.com

6 may 2026, 22:25 UTC

Charlas de Mercado

Canada's Public Finances on Sustainable Path, BOC's Macklem Says -- Market Talk

6 may 2026, 22:11 UTC

Ganancias

Taseko Mines Ltd. 1Q Adj EPS C$0.08 >TKO.LN

6 may 2026, 22:11 UTC

Ganancias

Taseko Mines Ltd. 1Q EPS C$0.05 >TKO.LN

6 may 2026, 22:05 UTC

Charlas de Mercado

Updated Govt Fiscal Plan Won't Have Sizable Impact on BOC Outlook -- Market Talk

6 may 2026, 21:58 UTC

Ganancias

Arm Stock Takes Wild Ride After Earnings. Demand Might Be Too Strong to Meet. -- Barrons.com

6 may 2026, 21:47 UTC

Charlas de Mercado

Ganancias

Costco Posts 13% Sales Growth in April -- Market Talk

6 may 2026, 21:46 UTC

Ganancias

IonQ Doubles Down on Nvidia Comparison. Why the Stock Is Falling After Blowout Earnings. -- Barrons.com

6 may 2026, 21:40 UTC

Ganancias

Arm Stock Takes Wild Ride After Earnings. Demand Might Be Too Strong to Meet. -- Barrons.com

6 may 2026, 21:35 UTC

Charlas de Mercado

BOC's Macklem Defends Warning About Rate Hikes to Fight Inflation -- Market Talk

6 may 2026, 21:32 UTC

Acciones populares

Stocks to Watch Wednesday Recap: Advanced Micro Devices, Flutter, Disney, Uber -- WSJ

6 may 2026, 21:29 UTC

Ganancias

Fastly Stock Tumbles. An Earnings Beat Pauses a Monster Rally. -- Barrons.com

Comparación entre iguales

Cambio de precio

Ultragenyx Pharmaceutical Inc previsión

Precio Objetivo

By TipRanks

111.85% repunte

Estimación a 12 Meses

Media 52.56 USD 111.85%

Máximo 84 USD

Mínimo 25 USD

De acuerdo con 18 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Ultragenyx Pharmaceutical Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

18 ratings

Comprar

Mantener

Vender

De acuerdo con 18 analistas que ofrecen calificaciones bursátiles a para Ultragenyx Pharmaceutical Inc Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

32.76 / 39.24Soporte y Resistencia

Recent bearish events outweigh bullish events.

All events are bearish.

Sentimiento

By Acuity

154 / 347 Clasificación en Sanidad

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Ultragenyx Pharmaceutical Inc

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc.; Solid Biosciences Inc.; Regeneron; Abeona; and Daiichi Sankyo Co., Ltd. The company was incorporated in 2010 and is headquartered in Novato, California.